Undialyzed patients with chronic renal failure
Conditions
Interventions
Treated by AST-120 6g daily for a period of 6 months
Not treated by AST-120 for a period of 6 months
Sponsors
Division of Nephrology, Department of Internal Medicine, Kawasaki Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Medications have not been changed in the last 6 months. (2) Blood pressures have been controlled appropriately in the last 6 months. (3) HbA1c levels have been stable within +/-0.5% changes in the last 6 months. (4) Over 20 years of age. (5) Patients with the informed consent to this study.
Exclusion criteria
Exclusion criteria: (1) Patients with obstructive or stenotic diseases of digestive organs. (2) Patients with the nephrotic syndrome. (3) Patients with acute renal failure, rapid elevation of serum creatinine or active nephropahty in the last 6 months. (4) Patients with inflammatory or consumptive diseases (e.g. infection, malignancy). (5) Patients with severe cardiovascular diseases (e.g. heart failure, coronary disease, cerebrovascular disease, peripheral vascular disease). (6) Dialyzed patients. (7) Patients treated by AST-120. (8) Patients treated by steroids or immunosuppressive agents. (9) Females in pregnancy. (10) Patients judged as unsuitable for participating in this study by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flow-mediated vasodilation of branchial artery | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of the below parameters: (1) Systolic and diastolic blood pressure (2) Creatinine clearance (Ccr) (3) Urinary protein excretion (UPE) (4) Mediators associated with endothelial function | — |
Countries
Japan
Contacts
Public ContactYuko Nishi
Kawasaki Medical School Division of Nephrology, Department of Internal Medicine
Outcome results
None listed